Fat emulsions and lung function.
IVFE infusion can impair lung function in healthy adults, premature infants, and adults with pre-existing lung injury, and in experimental animals with acute injury. Although all observed IVFE-related lung dysfunction was initially attributed to the temporally associated hyperlipemia, this explanation may in fact be correct only with fat overload syndrome. When serum triglyceride levels are in a more appropriate range, all subsequent studies have shown the same alterations in lung function unrelated to triglyceride increases and indomethacin-related blocking of lung function impairment, despite comparable serum triglyceride increases. Furthermore, our studies with Liposyn demonstrated the most significant increases in serum triglyceride levels, but the smallest PaCO2 and PaO2 changes. In general, the lung function abnormalities associated with IVFE infusion have thus been caused by increases in VA/Q inequalities. Although elucidation of the relationship between IVFE-related increased PG production and secondary VA/Q changes may be of significant physiologic import, the PaO2 and PaCO2 changes even with pre-existing lung injury have generally not been of sufficient magnitude to be of much clinical significance. The IVFE-related increases in plasma PG concentrations may, however, still have significant nonpulmonary clinical effects related to known or postulated consequences of increased plasma PG concentrations, including effects on ductus arteriosus patency, retinal and cerebral blood flow, and immune competence.
Hageman
J R
JR
Hunt
C E
CE
D000328:Adult; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D002245:Carbon Dioxide / Q000097:blood; D002648:Child; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects* / Q000378:metabolism; D005228:Fatty Acids, Essential / Q000172:deficiency; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D010100:Oxygen / Q000097:blood; D011453:Prostaglandins / Q000096:biosynthesis / Q000097:blood; D011653:Pulmonary Diffusing Capacity / Q000187:drug effects; D011817:Rabbits; D012756:Sheep; D014280:Triglycerides / Q000097:blood; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects
D001095:Arachidonic Acids; D005217:Fat Emulsions, Intravenous; D005228:Fatty Acids, Essential; D011453:Prostaglandins; D014280:Triglycerides; D002245:Carbon Dioxide; D016718:Arachidonic Acid; D010100:Oxygen